[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100361552":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":24,"responsibleParty":42,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":83,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Future Genetics Limited","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Displaying trait of interest",null,"There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.",{"label":13,"type":10,"description":14,"interventionNames":10},"Not displaying trait of interest","Please see above.",[16],{"name":17,"affiliation":5,"role":18},"Dr Mohammed Kamran","STUDY_DIRECTOR",[20],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","00441216673007","director@futuregenetics.co.uk",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Future Genetics, The Science Centre, Wolverhampton Science Park","RECRUITING","Wolverhampton","West Midlands","WV10 9RU","United Kingdom","UK",{"type":34,"coordinates":35},"Point",[36,37],-2.12296,52.58547,{"lat":37,"lon":36},[40],{"name":41,"role":21,"phone":22,"phoneExt":10,"email":23},"Mohammed Kamran, PhD",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100361552","empower-1-a-multi-site-clinical-cohort-research-study-to-reduce-health-inequality-100361552",false,"NCT03987633","EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population","EMPOWER","Inclusion Criteria:\n\n1. Patients or their relative\u002Ffamily member is diagnosed with the illness being investigated by this study.\n2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study.\n3. Subjects agree to:\n\n   1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient.\n   2. Provide Consent for access to medical records.\n   3. Complete disease specific, quality of life, and study associated questionnaires.\n\nExclusion Criteria:\n\n1. Patient does not provide a valid consent for study participation.\n2. Patient is not registered with the NHS for care.\n3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study.\n4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.",true,"ALL","6 Years",{"count":56,"type":57},200000,"ESTIMATED","OBSERVATIONAL","Health inequality and genetic disparity are a significant issue in the United Kingdom (UK).\n\nThis study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations.\n\nThe vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that participated in the drug licencing clinical trials. A consequence of this is that drugs are licensed for use in real-world general patient populations where the clinical trial results are simply not statistically significant to specifically demonstrate efficacy or safety in populations that were either absent or under-represented in the drug registration clinical trials. When these facts are considered alongside data that supports significant under-reporting of adverse events in the real-world setting within the UK (and globally, e.g the USA and Europe), it highlights that pharmacovigilance systems are unable to capture drug effectiveness and safety data in a manner that can reasonably assure appropriate prescribing in the wider patient populations.\n\nThis large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK.\n\nThe goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.",[61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"Atrial Fibrillation","Coronary Heart Disease","Cardiovascular Diseases","Heart Failure","Hypertension","Peripheral Arterial Disease","Stroke, Ischemic","Asthma","Chronic Obstructive Pulmonary Disease","Obesity","Cancer","Chronic Kidney Diseases","Diabetes Mellitus","Dementia","Depression","Epilepsy","Mental Health Disorder","Rheumatoid Arthritis","Blood Pressure","Breast Cancer Risk","Prostate Cancer","Lung Cancers",[84,85,86,87,88],"genetic disparity","health inequality","genetics","health outcomes","equality","2025-03-05",{"date":91,"type":92},"2025-03-10","ACTUAL",{"date":94,"type":92},"2020-02-01",{"date":96,"type":57},"2030-02-01",{"name":5,"class":6},1]